1258MO Low dose versus standard dose pembrolizumab for treatment of stage IV stage non-small cell lung carcinoma: Results of the pre-planned interim analysis of the NVALT-30 clinical trial

DOI: 10.1016/j.annonc.2024.08.1315 Publication Date: 2024-09-17T20:27:33Z